Sweden's Combigene Readies Gene Therapy For Epilepsy Trials
Executive Summary
CombiGene CEO tells Scrip the Swedish biotech seeks a big pharma partner to develop its lead asset CG01 as a therapy for drug-resistant epilepsy.
You may also be interested in...
CEO of New UK Cell And Gene Therapy Hub Says 'All Systems Are Go'
CEO of the Stevenage-based center hopes the new cell and gene manufacturing hub will see a growing life sciences ecosystem coalesce around it.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.